User login
Key clinical point: Adding abiraterone plus prednisone to androgen deprivation therapy (ADT) following definitive treatment in patients with biochemically recurrent castration-naïve prostate cancer prolongs prostate-specific antigen (PSA)-free survival (PSA less than 0.2 ng/mL).
Major finding: Abiraterone and prednisone plus ADT vs ADT alone significantly improved PSA-free survival (27.0 months vs 19.9 months; hazard ratio, 0.64; 95% confidence interval, 0.47-0.87).
Study details: A phase 2, randomized, open-label trial of 200 patients with nonmetastatic biochemically recurrent castration-naïve prostate cancer who were randomly assigned to either abiraterone plus prednisone to ADT or ADT alone following definitive treatment.
Disclosures: This study was funded by the Prostate Cancer Foundation, Janssen Research, Koch Center for Applied Biology, and Alexander & Eckstein Labs. The authors received research grant/funding, honoraria, advisory/consulting fees, and travel expenses. Dr. Subudhi SK declared ownership interest with Apricity Health.
Source: Spetsieri N et al. Eur J Cancer. 2021 Sep 15. doi: 10.1016/j.ejca.2021.06.017.
Key clinical point: Adding abiraterone plus prednisone to androgen deprivation therapy (ADT) following definitive treatment in patients with biochemically recurrent castration-naïve prostate cancer prolongs prostate-specific antigen (PSA)-free survival (PSA less than 0.2 ng/mL).
Major finding: Abiraterone and prednisone plus ADT vs ADT alone significantly improved PSA-free survival (27.0 months vs 19.9 months; hazard ratio, 0.64; 95% confidence interval, 0.47-0.87).
Study details: A phase 2, randomized, open-label trial of 200 patients with nonmetastatic biochemically recurrent castration-naïve prostate cancer who were randomly assigned to either abiraterone plus prednisone to ADT or ADT alone following definitive treatment.
Disclosures: This study was funded by the Prostate Cancer Foundation, Janssen Research, Koch Center for Applied Biology, and Alexander & Eckstein Labs. The authors received research grant/funding, honoraria, advisory/consulting fees, and travel expenses. Dr. Subudhi SK declared ownership interest with Apricity Health.
Source: Spetsieri N et al. Eur J Cancer. 2021 Sep 15. doi: 10.1016/j.ejca.2021.06.017.
Key clinical point: Adding abiraterone plus prednisone to androgen deprivation therapy (ADT) following definitive treatment in patients with biochemically recurrent castration-naïve prostate cancer prolongs prostate-specific antigen (PSA)-free survival (PSA less than 0.2 ng/mL).
Major finding: Abiraterone and prednisone plus ADT vs ADT alone significantly improved PSA-free survival (27.0 months vs 19.9 months; hazard ratio, 0.64; 95% confidence interval, 0.47-0.87).
Study details: A phase 2, randomized, open-label trial of 200 patients with nonmetastatic biochemically recurrent castration-naïve prostate cancer who were randomly assigned to either abiraterone plus prednisone to ADT or ADT alone following definitive treatment.
Disclosures: This study was funded by the Prostate Cancer Foundation, Janssen Research, Koch Center for Applied Biology, and Alexander & Eckstein Labs. The authors received research grant/funding, honoraria, advisory/consulting fees, and travel expenses. Dr. Subudhi SK declared ownership interest with Apricity Health.
Source: Spetsieri N et al. Eur J Cancer. 2021 Sep 15. doi: 10.1016/j.ejca.2021.06.017.